Diana Bracco: “With Blue Earth we are bolstering our global leadership in diagnostic imaging”

Milan, Italy , 07/02/2019

Bracco Imaging’s acquisition of the British firm Blue Earth Diagnostics is "an important agreement that we are extremely proud of, a strategic agreement that significantly enhances our portfolio in the area of precision medicine and customised diagnostics, while also expanding our offerings in the field of nuclear oncological imaging in urology and other specialties". The President and Chief Executive Officer of the Bracco Group, Diana Bracco, was laying the foundation stone of the new extension to the Bracco facility situated in Plans-Les-Ouates, Geneva, when she released this comment about the acquisition of the UK-based firm.

"With this acquisition we aim to provide doctors and their patients all around the world with the best possible support,” added Diana Bracco. “Blue Earth Diagnostics, with its 100 employees and $US 140 million in revenues, owns a ground-breaking molecular imaging agent that has already been approved in the USA and Europe for use with PET scans in cases of suspected recurrent prostate cancer. The deal, which follows that of SurgVision in 2017, marks yet another milestone for Bracco, exactly 25 years after our landmark acquisition: Squibb Diagnostics. With that purchase, back in 1994, we realised our American dream”.

Blue Earth we are bolstering our global leadership in diagnostic imaging”